Dicerna Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dicerna Pharmaceuticals, Inc.
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
The UK's Silence Therapeutics is moving its candidate products into early clinical studies in cardiovascular diseases and improving its visibility with a NASDAQ listing.
At EASL 2020, four partnerships updated RNA-interference or antisense efforts to reduce hep B surface antigen, believed to lead to functional cure of the virus. One analyst sees J&J/Arrowhead as the early leader.
Novo Nordisk’s 6 August Q2 update will be scrutinized for clues on its plans for semaglutide in obesity, sales data for diabetes drugs Rybelsus and Ozempic, and likely M&A.
- Antisense, Oligonucleotides
- Large Molecule